<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[MGC Pharmaceuticals - Medium]]></title>
        <description><![CDATA[The official MGC Pharmaceuticals Blog. - Medium]]></description>
        <link>https://medium.com/mgc-pharmaceuticals?source=rss----e8968cc8025d---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>MGC Pharmaceuticals - Medium</title>
            <link>https://medium.com/mgc-pharmaceuticals?source=rss----e8968cc8025d---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Mon, 16 Nov 2026 02:19:21 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/mgc-pharmaceuticals" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[UPDATE: CannEpil™ production has officially commenced]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/update-cannepil-production-has-officially-commenced-7cdc4af48ff6?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/7cdc4af48ff6</guid>
            <category><![CDATA[updates]]></category>
            <category><![CDATA[product]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[cannepil]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <dc:creator><![CDATA[Ron Lipsky]]></dc:creator>
            <pubDate>Thu, 05 Apr 2018 00:26:33 GMT</pubDate>
            <atom:updated>2018-10-15T22:09:58.961Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*k52rOfBUSlVgvh4vpfhgQQ.jpeg" /></figure><p><em>A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals.</em></p><p>Thursday March 29 was a day of celebration on MGC Pharma’s timeline as we announced the commencement of production for the first batch of CannEpil™.</p><p>CannEpil™ — CBD-based treatment for people with Refractory Epilepsy — is <a href="https://medium.com/mgc-pharmaceuticals/cannepil-the-first-product-from-mgc-pharma-e368bacbaf9a">the first product we’ve released to market</a>. After years of testing the effects of CBD on patients with Epilepsy, we’re thrilled to finally see our hard work come to fruition, not just for the sake of progress in the Medical Cannabis industry, but also for the many people suffering from severe Epilepsy and seizures across the world.</p><p>According to the World Health Organisation (WHO), there are approximately 50 million people currently living with a form of Epilepsy throughout the world, and of those 50 million, 30% have Refractory Epilepsy. 72,000 of those are Australians.</p><p>Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CBD has recently been <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1611618?query=featured_home">proven</a> to reduce the severity of seizures, which is another reason we are so excited to begin production of CannEpil™ and take a huge step towards distribution in local and international markets.</p><p>Now that we’ve achieved this milestone (following the receipt of interim GMP certification), we’re refocusing our energy on achieving full GMP certification for our European Medical Cannabis laboratory and production facility. This requires further analysis and validation (which will follow next month), where the batch will be inspected by the GMP regulatory body to ensure all protocols were followed during production. Once we do receive full GMP certification, our lab will become one of Europe’s most advanced facilities for pharmaceutical grade Medical Cannabis compounding and will also put us on track to becoming an international pioneer in Phytocannabinoid-based medicine within the biopharmaceutical industry.</p><p>The green light from the International Society for Pharmaceutical Engineering will then allow us to begin full-scale commercial production of CannEpil™, as well as developing additional pharmaceutical grade Medical Cannabis products for use in our future clinical studies, research pipelines and for public distribution.</p><p>This is an extremely exciting step forward for MGC Pharma as we seek to solve serious health issues both here in Australia and across the world, and I look forward to commencing full scale commercial production of CannEpil™ in the next few months.</p><p>You can read the full ASX announcement <a href="http://www.investi.com.au/api/announcements/mxc/89f785cd-533.pdf">here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7cdc4af48ff6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/update-cannepil-production-has-officially-commenced-7cdc4af48ff6">UPDATE: CannEpil™ production has officially commenced</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Introducing MGC Nutraceuticals]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/introducing-mgc-nutraceuticals-101acbe0500f?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/101acbe0500f</guid>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[mgcpharma]]></category>
            <category><![CDATA[ecommerce]]></category>
            <category><![CDATA[news]]></category>
            <category><![CDATA[mgc-nutraceuticals]]></category>
            <dc:creator><![CDATA[Ron Lipsky]]></dc:creator>
            <pubDate>Wed, 14 Mar 2018 05:00:15 GMT</pubDate>
            <atom:updated>2018-03-14T05:00:14.660Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*8uO2BYIkEW9FbMSyMUICog.jpeg" /><figcaption>MXC’s fourth division: MGC Nutraceuticals</figcaption></figure><p>MGC Pharmaceuticals will be taking its first step into the world of nutraceuticals with the creation of our new brand, MGC Nutraceuticals.</p><p>MGC Nutraceuticals will allow us to create more dynamic products that, unlike MGC Pharma products, don’t require a prescription, and can be sold anywhere, anytime.</p><p>However, the point of difference that these products have from other nutraceutical products on the market, is that they are more premium, coming from our GMP-certified facility in Slovenia.</p><p>We believe that these high quality, pharmaceutical-grade phytocannabinoid products will stand out from other products in the nutraceutical market and help users achieve balance, wellness and homeostasis.</p><p>To launch MGC Nutraceuticals, we are currently developing an online store where MGC Nutraceutical products will be available for sale in countries where phytocannabinoid-based products are legal, either in bulk to pharmacies and health stores, or to the general public.</p><p>We will be launching the website with eight products, that each contain different amounts of CBD so users can dictate for themselves how much they want to use to effectively treat their conditions.</p><p>The products being released for the launch are:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*03iLFepa9z-r7pqwGZFJdQ.jpeg" /></figure><p>You can learn more about MGC Nutraceuticals by visiting our current landing page. <a href="http://mgcnutraceuticals.com/">View the site here</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=101acbe0500f" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/introducing-mgc-nutraceuticals-101acbe0500f">Introducing MGC Nutraceuticals</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Medical Cannabis can unlock a higher quality of life for seniors]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/how-medical-cannabis-can-unlock-a-higher-quality-of-life-for-seniors-639b8eb176b8?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/639b8eb176b8</guid>
            <category><![CDATA[cannabidiol]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[medical-cannabis-access]]></category>
            <category><![CDATA[mgcpharma]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <dc:creator><![CDATA[Ron Lipsky]]></dc:creator>
            <pubDate>Fri, 23 Feb 2018 03:39:09 GMT</pubDate>
            <atom:updated>2018-02-23T03:39:09.340Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*b7bwv98EE6joEO8SZoVdmA.png" /><figcaption>How Medical Cannabis can unlock a higher quality of life for seniors</figcaption></figure><p><em>A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals</em></p><p>While we spend a lot of time discussing the advantages of Medical Cannabis to Australia as a whole, there are specific age groups and demographics that stand to benefit the most from unrestricted access — namely Australia’s aging population.</p><p>According to the Australian Bureau of Statistics, the number of people aged 65 years or older is expected to exceed the number of children aged 14 and below by as soon as 2030. Though it’s a testament to medical, surgical and general health-related advancements that our seniors are living longer, the reality is that <a href="https://ndarc.med.unsw.edu.au/blog/older-australians-are-key-driver-increased-prescription-painkiller-deaths">their dependence on opioids</a> is more prevalent and dangerous than ever.</p><p>While at home in Australia, the Medical Cannabis industry is still working hard to gather more evidence-based research to substantiate treatment assertions, relevant studies are already occurring overseas. <a href="https://health.hawaii.gov/medicalcannabis/files/2018/01/FY18-December-31-2017-19858-Valid.pdf">A recent Hawaii-based study</a> of 2,736 patients above the age of 65 found that, after six months, 93.7% of respondents who received Medical Cannabis treatment reported improvement in their condition and significant reductions to pain levels.</p><p>What’s more encouraging is that after a period of six months of using Medical Cannabis,18.1% stopped using opioid analgesics or were able to reduce their dose. The study concluded that the “therapeutic use of cannabis is safe and efficacious in the elderly population”.</p><p>On our own soil, the awareness of Medical Cannabis’ potential to improve the quality of life for Australian seniors is growing. An increasing number of older people are seeking the treatment for conditions such as inflammatory arthritis, autoimmune disease and chronic pain. Unfortunately, the regulatory process is fraught with bottlenecks, with no more than 500 Australians having legal access to Medical Cannabis. Understandably, no major regulatory or medical progress can be made without significant evidence. Bill Boyd, President of the Australian Medical Association, explained that it was important for legislation to proceed incrementally in line with medical research,</p><p>“[It is] like every other medication which may be destined to be released. It has to be done properly… Clearly huge strides have been taken towards possible use of this agent as a medication, but until such time as we are all satisfied that it is safe to use … then it will remain under very restricted release.”</p><p>It’s heartening to see the release of more and more evidence-based global research surrounding Medical Cannabis-based treatment. MGC Pharmaceuticals is committed to furthering the awareness of Cannabis’ treatment benefits, and we only hope that with greater investment in R&amp;D on our own soil, one day soon our own medical system can provide the pain relief our growing population deserves.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=639b8eb176b8" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/how-medical-cannabis-can-unlock-a-higher-quality-of-life-for-seniors-639b8eb176b8">How Medical Cannabis can unlock a higher quality of life for seniors</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Australia Looks Primed For The Top Spot In The Global Cannabis Market]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/australia-looks-primed-for-the-top-spot-in-the-global-cannabis-market-8443c4a2b5f5?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/8443c4a2b5f5</guid>
            <category><![CDATA[australia]]></category>
            <category><![CDATA[cannabidiol]]></category>
            <category><![CDATA[mgcpharma]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[medical-marijuana]]></category>
            <dc:creator><![CDATA[Ron Lipsky]]></dc:creator>
            <pubDate>Thu, 22 Feb 2018 00:56:28 GMT</pubDate>
            <atom:updated>2018-02-22T00:56:28.289Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*hikE6eraag1RIzpuO6NM-w.jpeg" /><figcaption>Australia Looks Primed For The Top Spot In The Global Cannabis Market</figcaption></figure><p><em>A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals</em></p><p>The last twelve months have seen a lot of exciting changes and advancements for MGC Pharmaceuticals, particularly our research collaboration with RMIT, <a href="https://medium.com/mgc-pharmaceuticals/cannepil-the-first-product-from-mgc-pharma-e368bacbaf9a">the unveiling of CannEpil™</a>, and the introduction of our new dermatological product — TopiCann. 2017 also saw the legalisation of Medical Cannabis importation and distribution for approved Australian companies earlier in the year.</p><p>2018, however, is already proving to be yet another historical timestamp in the quest for more Phytocannabinoid-inclusive global health solutions. The federal government’s recent decision to allow medicinal cannabis exports looks set to add even more momentum to Australia’s growing dominance in the international medicinal cannabis market.</p><p><a href="https://www.sbs.com.au/news/australia-expected-to-become-world-s-top-medicinal-cannabis-supplier-health-minister">Our Australian Health Minister, Greg Hunt,</a> believes that the move will not only assist overseas markets, but also help grow the developing market here on Australian soil.</p><p><em>“By helping the domestic manufacturers to expand, this, in turn, helps to ensure an ongoing supply of Medicinal Cannabis products here in Australia,” </em>Says Hunt.</p><p>Armed with a well-developed agricultural sector, high environmental standards, world class pharmaceutical manufacturing standards, a like-minded government, and grassroot support for the industry, there can be no doubt that <a href="http://www.abc.net.au/news/2018-01-04/australia-seeks-global-domination-of-medical-cannabis-market/9302524">Australia is poised to become a Medical Cannabis powerhouse.</a></p><p>For MGC Pharma, this means that our place in both the local and international market puts us in a position of leadership. Our extensive real-world, technical and professional experience is increasingly making MGC Pharma a brand of influence in global public health.</p><p>One barrier in the way of our country leading a $55 billion global market, however, is the national system of regulation for Medical Cannabis. Currently in Australia there is very limited patient access, firm restrictions on production and an arduous prescription process in place for medical professionals. As a result, these formal roadblocks have opened the industry up to black market operators who are now profiting from the unlicensed sale of Cannabis oil. All of this is money that could funneled back into the research and development of Cannabis-based medications.</p><p>Right now, however, our focus is on navigating the current national regulatory system, developing advanced biopharmaceutical solutions and improving patient access and results. Our number one priority is and always will be improving the lives of patients all over the world.</p><p>It’s a climactic time for the Medical Cannabis industry. We’re excited to be leading the charge in CBD-based patient treatment within Australasia and we can’t wait to watch its growing role in delivering global health solutions.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8443c4a2b5f5" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/australia-looks-primed-for-the-top-spot-in-the-global-cannabis-market-8443c4a2b5f5">Australia Looks Primed For The Top Spot In The Global Cannabis Market</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Top Medical Cannabis Research of 2017]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/the-top-medical-cannabis-research-of-2017-9eb8b6303642?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/9eb8b6303642</guid>
            <category><![CDATA[mgcpharma]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[medical-cannabis-industry]]></category>
            <category><![CDATA[cannabis-research]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <dc:creator><![CDATA[Ron Lipsky]]></dc:creator>
            <pubDate>Tue, 20 Feb 2018 23:39:27 GMT</pubDate>
            <atom:updated>2018-02-20T23:39:27.407Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*eaORwe1oLd1_qm5y3P6pbg.jpeg" /><figcaption>The Top Medical Cannabis Research of 2017</figcaption></figure><p><em>A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals</em></p><p>MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon. One of the reasons that 2018 could be very exciting for MGC Pharma is all the positive Medical Cannabis research that took place last year, with many new findings being made that could positively affect the future of the industry.</p><p>In this blog, I will explore some of the top Medical Cannabis Studies of 2017 and discuss what the findings mean for the future of the Medical Cannabis industry.</p><h4><strong>Cannabis is an effective tool for the treatment of topical skin conditions</strong></h4><p>In a recent study by undertaken by MGC Pharma, our dermatologists found that CBD is effective in providing relief for relief for dry, red, flakey, oily and acne prone skin through CBD skincare.</p><p>These studies were undertaken in preparation for the release of the clinically trialled <em>TopiCann </em>skincare product.</p><p>Researched and developed by Slovenia’s leading dermatologist, Dr Rok Devjak, MD PhD, over an 80 day period, Dr Devjak tested three of MGC Pharma’s upcoming products.</p><p>The three products tested showed a strong improvement in these topical skin conditions, helping to reduce the appearance of dry, red and flakey skin within 4 weeks*. Additionally, Dr Devjak observed an 80% improvement of irritated skin and over 70% improvement in the visual appearance of itching and dry skin.</p><h4><strong>CBD passes Stage 3 clinical trial for the treatment of epilepsy in children</strong></h4><p>A<a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1611618#t=article"> study</a> published last year in The New England Journal of Medicine saw scientists studying the effects of CBD on epileptic seizures in patients with Dravet syndrome, a severe epileptic disorder leading to frequent and uncontrollable seizures in children.</p><p>The researchers found that CBD oil reduced the number of seizures in children by 39% and these results were achieved with minimal side effects.</p><p>This is the largest and most successful clinical trial to-date to demonstrate the medicinal benefits of CBD, and it will likely convince many clinicians to consider CBD for treating the 20% of epileptic disorders that are poorly controlled by traditional anti-epileptic drugs.</p><h4><strong>Autism was added to the list of CBD’s medicinal benefits</strong></h4><p>Last year, scientists at the University of Washington looked at CBD’s impact on autistic-like social deficits, and<a href="http://www.pnas.org/content/114/42/11229.abstract"> their research</a> revealed that CBD normalises social behaviour in mice.</p><p>The scientists found that CBD increased the mice’s preference for spending time interacting with other mice and reduced the number of social anxiety-like behaviours.</p><h4><strong>Cannabis is a powerful weapon against the opioid epidemic</strong></h4><p>One of the biggest health news stories of 2017 has been the escalating need to address the opioid crisis taking place across the world.</p><p>Association studies over the last couple of years have identified that there are fewer opioid-related overdoses in states with access to Medicinal Cannabis.</p><p><a href="https://www.ncbi.nlm.nih.gov/pubmed/28189912">One</a> study surveyed 271 Canadian patients who were seeking prescription drug treatment for a variety of ailments including pain, anxiety, and depression; among these, 63% reported that Cannabis substituted for their prescription medications. Specifically, among pain patients, 30% reported that they swapped out their prescription opioids for Cannabis. Patients reported that one of their greatest reasons for switching from opioids to Cannabis wasn’t necessarily because of better symptom management, but because there were fewer side effects associated with Cannabis use.</p><p>University of New Mexico scientists<a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187795"> researched</a> the substitutability of Cannabis for opioids to the test in a cohort of chronic pain patients. The study compared prescription opioid use, mostly to treat back pain, between patients enrolled or not enrolled in New Mexico’s Medical Cannabis Program. They found that 84% of patients who received access to Medical Cannabis reduced their opioid prescriptions, compared to 45% in the comparison group. Notably, 41% of the Cannabis users stopped using opioids altogether.</p><p>These studies are the latest to support Cannabis’ benefits in reducing opioid use. They find that Cannabis can either substitute for prescription pain medication or supplement its effect, thus requiring fewer opioid pills to be consumed.</p><h4><strong>Cannabis reduces the symptoms of Parkinson’s disease</strong></h4><p>Cannabis cannot cure Parkinson’s disease, but there’s now evidence that Cannabis can relieve many of the devastating symptoms associated with the disease.</p><p>In a<a href="https://www.ncbi.nlm.nih.gov/pubmed/29059132"> study</a> of 40 Parkinson’s disease patients, scientists from Tel Aviv University in Israel found that Medicinal Cannabis improved many of the symptoms associated with the disease.</p><p>82% of participants reported that Medical Cannabis improved their overall symptoms. Cannabis reduced the number of falls, provided pain relief, reduced tremors, soothed muscle stiffness, and improved sleep. Nearly 75% also reported that Cannabis enhanced their mood, suggesting that Cannabis may be an effective palliative care strategy for Parkinson’s disease patients.</p><p>The results of all the above research are very exciting for MGC Pharma, as they reveal the potential for an expanded market in the future for Medical Cannabis products. We will continue to follow these findings with great interest, and help to create a healthier world through the use of Medical Cannabis.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9eb8b6303642" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/the-top-medical-cannabis-research-of-2017-9eb8b6303642">The Top Medical Cannabis Research of 2017</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What will unrestricted access to Medicinal Cannabis look like in Australia?]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/what-will-unrestricted-access-to-medicinal-cannabis-look-like-in-australia-e5e10740b159?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/e5e10740b159</guid>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[epilepsy]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[medical-marijuana]]></category>
            <category><![CDATA[australia]]></category>
            <dc:creator><![CDATA[Ron Lipsky]]></dc:creator>
            <pubDate>Fri, 16 Feb 2018 05:28:41 GMT</pubDate>
            <atom:updated>2018-02-16T05:28:41.338Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*WeqBk5m_qIUJ05KKqB0bjg.jpeg" /><figcaption>What will unrestricted access to Medicinal Cannabis look like in Australia?</figcaption></figure><p><em>A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals</em></p><p>Right now in Australia, access to Cannabis-based treatments is heavily restricted. Physicians who want to prescribe Medicinal Cannabis are required to jump through countless regulatory hoops, as are patients seeking treatment. However, we’re proud to report that each year in Australia progress is being made to increase access to Medicinal Cannabis here on our own soil.</p><p>In 2016, growing Cannabis for scientific and medicinal purposes was made legal; in 2017, the first Cannabis Research license was issued; and just this year the federal government moved to <a href="http://www.abc.net.au/news/rural/2018-01-04/australian-medicinal-cannabis-firm-welcomes-export-opportunities/9303830">legalise Medicinal Cannabis exports. </a>Though the regulatory system is providing a number of hurdles for the medicinal movement, progress is certainly being made on the treatment front with more and more medical trials occurring every year. And though the benefits of Medicinal Cannabis are currently being utilised by only a small number of patients, the future’s certainly looking brighter for pain sufferers in Australia.</p><p>So, what does the future of unrestricted access to Medicinal Cannabis look like?</p><p>Not only would Australia get a large piece of the $55 billion global market thanks to international exports, but Medicinal Cannabis would be accessible to tens of thousands of chronic pain sufferers throughout Australia.</p><p>In 2016, we released a <a href="https://mgcpharma.com.au/wp-content/uploads/2016/03/mgc_whitepaper_final-sml.pdf">white paper in partnership with the University of Sydney</a> that showed, if unrestricted, there would be a demand for roughly <a href="https://www.sbs.com.au/news/victoria-s-medical-cannabis-trial-to-treat-children-with-severe-epilepsy-successful">404.7 kg of CBD and 163.7 kg of THC per annum for Epilepsy, MS and HIV/Aids sufferers alone</a>. When calculated according to per-annum consumption in case study countries such as Israel, Canada and the Netherlands, this number ballooned to at least 8,000 kg of cannabis per annum. That’s 30,420 pain sufferers countrywide who would have access to alternate medication.</p><p>However, one distinct difference for Australians when compared to other unrestricted countries like the Netherlands is the unlikelihood that recreational Cannabis would be legal here. Currently, no influential figureheads in federal politics have spoken out in support of across the board legalisation. This means that while the future looks brighter for chronic pain sufferers, the same can’t be said for recreational usage.</p><p>Australia is a vital player in the global Medicinal Cannabis game. Its future looks rich in Cannabis production, export earnings and chronic pain treatment. In addition, our position of influence with Asia could translate to an opportune gateway for expanding the Cannabis movement throughout the world. As a result, MGC Pharmaceuticals is focused on continually raising awareness of the benefits of such treatment and are dedicated to the continued research and development of Cannabis-derived medical products. The fight for unrestricted access to Medicinal Cannabis is far from over but we’re determined to see it through until the end, for the benefit of the Australian people.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e5e10740b159" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/what-will-unrestricted-access-to-medicinal-cannabis-look-like-in-australia-e5e10740b159">What will unrestricted access to Medicinal Cannabis look like in Australia?</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Breaking Down The Cannabis Plant]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/breaking-down-the-cannabis-plant-cdf4829fbfff?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/cdf4829fbfff</guid>
            <category><![CDATA[cannepil]]></category>
            <category><![CDATA[cbd]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[cannabidiol]]></category>
            <category><![CDATA[cannabis]]></category>
            <dc:creator><![CDATA[Elad Segev]]></dc:creator>
            <pubDate>Wed, 13 Dec 2017 06:15:52 GMT</pubDate>
            <atom:updated>2017-12-13T06:15:51.631Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gGg-ip2hQQnaQ57hVxuuQA.jpeg" /></figure><p><em>A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals.</em></p><p>A Cannabis plant is made up of 400 different chemicals that have physical and psychoactive effects when consumed together. The addition or removal of these substances from a plant can cause very different results, which can potentially lower the efficacy of the plant.</p><p>Fortunately, at MGC Pharma, we are in the business of Medical Cannabis and have spent years researching and understanding the effects and phenotypes of different strains to determine which ones work best for different conditions, with each containing different amounts of THC, CBD and other components.</p><p>In this blog, I will introduce the prominent chemicals found in the Cannabis plant, as well as how they interact with the human body.</p><h4><strong>Cannabinoids</strong></h4><p>Many of the components found in Cannabis plants are known as cannabinoids. Cannabinoids will interact with neurological receptors in the human body in the same way that naturally occurring chemicals would. In fact, the human body is capable of producing its own set of endocannabinoids, which suggest that Cannabis has a significant role to play in regulating normal bodily functions.</p><p>Cannabinoids have the potential to affect everything in the human body, from your immune system, to your ability to remember short-term and long-term memories.</p><p>The more research that is done into cannabinoids derived from Cannabis, the more we will learn about the full effects they have on the human body.</p><h4><strong>Tetrahydrocannabinol (THC)</strong></h4><p>Tetrahydrocannabinol, or THC, is the component of the Cannabis plant that produces psychoactive effects that can range from racing thoughts to paranoia. While these effects tend to suggest that this component has few benefits outside of recreational use, there’s actually a lot more that THC is capable of.</p><p>In fact, there’s a lot of research that suggests THC can be very effective in several medical applications.</p><p>Firstly,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/"> recent research</a> has suggested that THC can help relieve pain in many patients. This is especially important when you take into consideration the major opioid crisis going on. You can learn more about that<a href="https://medium.com/mgc-pharmaceuticals/medical-cannabis-vs-the-opioid-crisis-c50dcb8dceeb"> here</a>. In short, THC medications could provide a much healthier alternative.</p><p>On top of its pain relief benefits, THC is also a well-known appetite stimulant. This effect can be put to very good use to help patients suffering from cancer or HIV/AIDS eliminate any uncomfortable nausea that their treatments provoke.</p><p>With so many potential benefits to offer, THC research represents a promising solution to many complex medical problems.</p><h4><strong>Cannabidiol (CBD)</strong></h4><p>Despite many people still associating Cannabis with its psychological effects, it’s very important to remember that it also contains substances that produce medical benefits without any impairment. Cannabidiol (CBD) is one of these components.</p><p>Patients suffering from disorders such as multiple sclerosis or PTSD may find some relief at the hands of CBD.</p><p>It’s also effective in treating patients with refractory epilepsy who experience daily seizures. In fact, MGC Pharma has just released their first product, CannEpil™, a CBD-based medication to help treat patients with refractory epilepsy. You can learn more about it<a href="https://medium.com/mgc-pharmaceuticals/cannepil-the-first-product-from-mgc-pharma-e368bacbaf9a"> here</a>.</p><p>As you can see, the Cannabis plant is a complex one, offering many medical benefits to people with all types of diseases. In time, we hope to learn more about the plants benefits and help deliver more treatments to patients with previously unmet medical needs.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cdf4829fbfff" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/breaking-down-the-cannabis-plant-cdf4829fbfff">Breaking Down The Cannabis Plant</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why Medical Cannabis Companies Must Work Together]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/why-medical-cannabis-companies-must-work-together-873224fb8257?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/873224fb8257</guid>
            <category><![CDATA[cannatech]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[cannabis]]></category>
            <category><![CDATA[medicinal-cannabis]]></category>
            <category><![CDATA[mgcpharma]]></category>
            <dc:creator><![CDATA[Ron Lipsky]]></dc:creator>
            <pubDate>Wed, 22 Nov 2017 05:57:10 GMT</pubDate>
            <atom:updated>2017-11-23T03:56:45.895Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*HI-_41zmSDhXDMJstgxYwg.jpeg" /><figcaption>Ron Lipsky — Cannatech London 2017</figcaption></figure><p><em>A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals.</em></p><p>I was lucky enough to be invited to give a talk at Cannatech UK several weeks ago, a fantastic event which brings together key figures in the Medical Cannabis industry.</p><p>This was a unique opportunity for me, as I realised I would be in a room full of my peers — like minded individuals who understand the benefits of Medical Cannabis and share my vision of creating a healthier world through its use.</p><p>Most people I speak to about the Medical Cannabis industry still don’t understand it’s full potential.. They giggle when I tell them about it, or they ask me if I can give them a free sample. It was this revelation that inspired the topic I would discuss at Cannatech UK: Why Medical Cannabis companies need to work together to change the public’s perception of the industry.</p><p>Every person working in this industry has faced the same image problems that I have. We work in an industry with three massive, highly competitive and often vicious industries leveraged against it.</p><p>An industry that will be associated with its underground past for at least the foreseeable future, as its legality struggles to gain global equilibrium.</p><p>An industry that needs to be taken seriously in order to achieve the lofty goals that we have all set for ourselves, which is to change the world and to make it a healthier, and better place.</p><p>All of us in this industry are here for a reason. We’ve suffered because we know there is suffering in the world that can be easily eliminated with the help of Medical Cannabis, but we haven’t had the chance to help.</p><p>And on a brighter note, we have seen the impact and change that Medical Cannabis products can have on people across the world, such as reducing seizures in children who would normally experience more than a hundred in a day.</p><p>What I’m saying is that in our industry, we know all about the good that Medical Cannabis can do, and it is our duty, all of us, to inform people about it as best we can. To guide them through everything we know, so that they can understand our industry a little bit better.</p><p>It’s the longer way around, for sure. It means more work for all of us. It means we have to learn more and be up to date on the science as well as the business. We need to ensure that we can explain concepts, that have taken us years to grasp, to people who are hearing about the potential of Medical Cannabis for the first time in their lives.</p><p>But it’s worth it. Every single time I explain what I do and why we are doing it, I have educated one more person, who can educate one more person, who can educate another, and another. This is something I call the ‘Realtime Entourage Effect’, which I have mentioned in a previous <a href="https://medium.com/mgc-pharmaceuticals/a-moment-on-the-entourage-effect-e430bdb43902">blog entry</a>.</p><p>Therefore, I call upon all of you to do this every time you talk to someone, be they a doctor, a patient, a legislator, a distributor, an investor, a customer, a vendor, or even your barista. Because every time you don’t do it, we are missing a chance to change the world for the better.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=873224fb8257" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/why-medical-cannabis-companies-must-work-together-873224fb8257">Why Medical Cannabis Companies Must Work Together</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Medical​ ​Cannabis​ ​vs.​ ​The​ ​Opioid​ ​Crisis]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/medical-cannabis-vs-the-opioid-crisis-c50dcb8dceeb?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/c50dcb8dceeb</guid>
            <category><![CDATA[cannabidiol]]></category>
            <category><![CDATA[mgcpharma]]></category>
            <category><![CDATA[cannabis-medical]]></category>
            <category><![CDATA[opioids]]></category>
            <category><![CDATA[medical-marijuana]]></category>
            <dc:creator><![CDATA[Nativ Segev]]></dc:creator>
            <pubDate>Thu, 16 Nov 2017 03:28:44 GMT</pubDate>
            <atom:updated>2017-11-16T05:17:34.217Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*H-vtW7HyRqMH-a4GWJ2I8Q.jpeg" /></figure><p><em>A</em>​ ​<em>word</em>​ ​<em>from</em>​ ​<em>Nativ</em>​ ​<em>Segev,</em>​ ​<em>Founder</em>​ ​<em>&amp;</em>​ ​<em>Managing</em>​ ​<em>Director</em>​ ​<em>of</em>​ ​<em>MGC</em>​ ​<em>Pharmaceuticals.</em></p><p>I​ ​want​ ​to​ ​talk​ ​about​ ​something​ ​a​ ​little​ ​bit​ ​different​ ​than​ ​usual.​ ​Something​ ​that​ ​has​ ​been​ ​a recurring​ ​theme​ ​in​ ​my​ ​newsfeed​ ​for​ ​the​ ​past​ ​several​ ​years:</p><p>Prescription​ ​opioids​ ​and​ ​the​ ​Opioid​ ​Crisis.</p><p>Prescription​ ​opioid​ ​painkillers​ ​are​ ​all​ ​too​ ​common​ ​and​ ​readily​ ​available​ ​in​ ​Australia,​ ​and​ ​that’s not​ ​a​ ​good​ ​thing.​ ​You​ ​might​ ​have​ ​read​ ​about​ ​the​ ​Opioid​ ​Crisis​ ​going​ ​on​ ​in​ ​the​ ​United​ ​States, where​ ​about​ ​142​ ​people​ ​are​ ​dying​ ​every​ ​day​ ​from​ ​accidental​ ​overdoses​ ​of​ ​prescription​ ​opioids​ ​– roughly​ ​60,000​ ​people​ ​last​ ​year.​ ​While​ ​the​ ​numbers​ ​aren’t​ ​nearly​ ​as​ ​bad​ ​as​ ​in​ ​the​ ​US, Australian’s​ ​are​ ​still​ ​at​ ​a​ ​huge​ ​risk​ ​of​ ​opioid​ ​addiction,​ ​ranking​ ​in​ ​at​ ​number​ ​8​ ​among​ ​the​ ​world’s top​ ​users​ ​of​ ​prescription​ ​opiates,​ ​with​ ​20,000​ ​doses​ ​being​ ​prescribed​ ​for​ ​every​ ​1​ ​million​ ​people.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/574/1*yRcqOyafUA7y5eXS4q-tdA.png" /></figure><p>Alex​ ​Wodak,​ ​the​ ​President​ ​of​ ​the​ ​Australian​ ​Drug​ ​Law​ ​Reform​ ​Foundation​ ​stated:​ ​“We​ ​doctors and​ ​pain​ ​specialists​ ​made​ ​a​ ​terrible​ ​error​ ​in​ ​the​ ​‘70s,​ ​‘80s​ ​and​ ​‘90s.​ ​We​ ​prescribed​ ​opiates​ ​too readily​ ​and​ ​at​ ​too​ ​high​ ​a​ ​dose​ ​to​ ​too​ ​many​ ​people.”</p><p>In​ ​fact,​ ​opiate-based​ ​pain​ ​medication​ ​is​ ​a​ ​large​ ​source​ ​of​ ​revenue​ ​in​ ​Australia,​ ​and​ ​it​ ​is​ ​definitely time​ ​that​ ​the​ ​government​ ​started​ ​considering​ ​safer​ ​alternatives​ ​to​ ​stop​ ​the​ ​issues​ ​that​ ​are plaguing​ ​the​ ​country.</p><p>You​ ​might​ ​be​ ​asking​ ​yourself​ ​why​ ​I​ ​am​ ​discussing​ ​the​ ​Opioid​ ​Crisis​ ​in​ ​a​ ​blog​ ​for​ ​a​ ​Medical Cannabis​ ​company,​ ​and​ ​the​ ​answer​ ​is​ ​simple.​ ​Medical​ ​Cannabis​ ​is​ ​one​ ​of​ ​the​ ​best​ ​ways​ ​to combat​ ​the​ ​opioid​ ​crisis,​ ​not​ ​just​ ​here​ ​in​ ​Australia,​ ​but​ ​across​ ​the​ ​world.</p><p>The​ ​Journal​ ​of​ ​the​ ​American​ ​Medicine​ ​Association​ ​(JAMA)​ ​published​​ ​​a​ ​study​​ ​that​ ​found​ ​states that​ ​had​ ​made​ ​Medical​ ​Cannabis​ ​legal​ ​had​ ​a​ ​24.8​ ​percent​ ​lower​ ​average​ ​annual​ ​opioid overdose​ ​death​ ​rate​ ​compared​ ​to​ ​states​ ​without​ ​Medical​ ​Cannabis​ ​laws.</p><p>How​ ​are​ ​the​ ​two​ ​connected,​ ​you​ ​might​ ​be​ ​asking.​ ​Well,​ ​research​ ​out​ ​of​ ​the​​ ​​University​ ​of Kentucky​​ ​has​ ​shown​ ​us​ ​that​ ​CBD,​ ​derived​ ​from​ ​Medical​ ​Cannabis,​ ​can​ ​significantly​ ​suppress chronic​ ​inflammatory​ ​and​ ​neuropathic​ ​pain,​ ​with​ ​no​ ​side​ ​effects.​ ​It’s​ ​not​ ​addictive​ ​and​ ​it’s impossible​ ​to​ ​overdose​ ​on.</p><p>Opiate​ ​painkillers​ ​only​ ​mask​ ​pain​ ​and​ ​can​ ​potentially​ ​be​ ​very​ ​addictive​ ​with​ ​the​ ​body​ ​able​ ​to build​ ​up​ ​a​ ​tolerance​ ​over​ ​time.​ ​CBD,​ ​on​ ​the​ ​other​ ​hand,​ ​​ ​is​ ​an​ ​effective​ ​anti-inflammatory​ ​that won’t​ ​lose​ ​effectiveness.</p><p>Prescribing​ ​Medical​ ​Cannabis​ ​as​ ​an​ ​alternative​ ​to​ ​opiates​ ​would​ ​do​ ​a​ ​lot​ ​to​ ​help​ ​end​ ​the​ ​Opioid Crisis​ ​across​ ​the​ ​world.​ ​While​ ​more​ ​research​ ​needs​ ​to​ ​be​ ​done​ ​before​ ​this​ ​can​ ​be​ ​actioned,​ ​at MGC​ ​Pharma,​ ​we​ ​stand​ ​by​ ​our​ ​vision​ ​of​ ​helping​ ​to​ ​heal​ ​the​ ​world​ ​through​ ​the​ ​use​ ​of​ ​Medical Cannabis,​ ​and​ ​the​ ​Opioid​ ​Crisis​ ​is​ ​no​ ​exception.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c50dcb8dceeb" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/medical-cannabis-vs-the-opioid-crisis-c50dcb8dceeb">Medical​ ​Cannabis​ ​vs.​ ​The​ ​Opioid​ ​Crisis</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[CannEpil™ — The first product from MGC Pharma]]></title>
            <link>https://medium.com/mgc-pharmaceuticals/cannepil-the-first-product-from-mgc-pharma-e368bacbaf9a?source=rss----e8968cc8025d---4</link>
            <guid isPermaLink="false">https://medium.com/p/e368bacbaf9a</guid>
            <category><![CDATA[mgcpharma]]></category>
            <category><![CDATA[medicinal-cannabis]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[cannepil]]></category>
            <category><![CDATA[epilepsy]]></category>
            <dc:creator><![CDATA[Roby Zomer]]></dc:creator>
            <pubDate>Thu, 02 Nov 2017 00:46:17 GMT</pubDate>
            <atom:updated>2017-11-02T01:30:51.971Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4LdxWgyouo3n--fs2OAMtA.jpeg" /></figure><p>This is a big moment for me and the MGC Pharmaceuticals team. Needless to say, I have been waiting a long time to write the following sentence:</p><p>MGC Pharmaceuticals has just released their first product to the market.</p><p>I’m very excited to announce the release of CannEpil™, a product that has been years in the making. CannEpil™ is CBD-based medication that is used as a treatment for people with refractory epilepsy.</p><p>We have been working hard testing the effects of CBD on patients with epilepsy, with our advisory team, Professor Uri Kramer and Professor David Neubauer, for the past two years.</p><p>All this hard work has led to the release of CannEpil™, which we couldn’t be more excited about, not just for MGC Pharma, but also for the many people suffering from severe epilepsy and seizures across the world.</p><p>According to the World Health Organisation (WHO), there are roughly 50 million people in the world with some form of epilepsy, and of those 50 million, 30% have refractory epilepsy.</p><p>Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CBD has recently been<a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1611618?query=featured_home"> proven</a> to reduce the severity of seizures, which is another reason we are so excited to release CannEpil™ into the market.</p><p>For a long time, it has been MGC Pharma’s vision to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and become a global leader in Phytocannabinoid-based medicines within the biopharmaceutical industry.</p><p>The release of CannEpil™ is our first step toward achieving this vision. And with many more products in the pipeline at MGC Pharma, we look forward to releasing many more products in the future that will continue to provide solutions to previously unmet medical needs and improve the lives of millions of people.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e368bacbaf9a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mgc-pharmaceuticals/cannepil-the-first-product-from-mgc-pharma-e368bacbaf9a">CannEpil™ — The first product from MGC Pharma</a> was originally published in <a href="https://medium.com/mgc-pharmaceuticals">MGC Pharmaceuticals</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>